Slide 1: Q3 2024 Business Update
Nasdaq: LUCD Q3 2024 Business Update November 13, 2024 Lishan Aklog MD Dennis McGrath Chairman & CEO CFO
Slide 2: Disclaimer
Disclaimer ▪ This presentation may contain certain forward-looking statements related to or Lucid Diagnostics Inc. (the “Company”) that involve risks and uncertainties. ▪ Actual results and events may differ significantly from results and events discussed in forward- looking statements. ▪ Factors th
Slide 3: Lishan Aklog, M.D. Chairman & CEO
Lishan Aklog, M.D. Chairman & CEO
Slide 4: Highlights
Highlights ▪ Commercial Execution – 3Q24 Revenue $1.2M: +20% Quarterly Record quarterly revenue – 3Q24 EsoGuard test volume 2,787 – Expanded direct contracting initiative with multiple programs focused on driving near-term revenue, building on first large #CYFT event with upfront contracted payment
Slide 5: Highlights
Highlights ▪ Key Strategic Accomplishments – ESOGUARD BE-1 clinical validation study accepted for peer-reviewed publication – Publication completes Lucid’s clinical evidence package for submission to formally seek Medicare coverage – Peer-reviewed publication of analytical validation study of EsoGua
Slide 6: Commercial-Stage Cancer Prevention Solution
COMMERCIAL- STAGE CANCER PREVENTION SOLUTION Comprehensive Precancer Screening Solution Our Mission is to Prevent Esophageal Cancer Deaths in At-risk Patients 6
Slide 7: EsoGuard Esophageal DNA Test
EsoGuard Esophageal DNA Test First and only commercially available test capable of serving as a widespread screening tool to prevent esophageal cancer deaths through early detection of esophageal precancer Recommended in major professional society clinical practice guidelines 7
Slide 8: EsoGuard Performance
EsoGuard Performance Vs. Comparable Early Detection Tests Sensitivity 89% Short Segment Early Precancer (SSBE) 96% 94% Sensitivity 88% 85% 83% 99% Overall Negative 42% Predictive Value (NPV) 13% 0% 0% Cancer Precancer Early Precancer 32% Positive Predictive EsoGuard Cologuard Guardant Shield Value (
Slide 9: EsoGuard Commercial Opportunity
EsoGuard Commercial Opportunity ~30 ~$60 Million X $1,938 = Billion At-Risk Patients Medicare Total Addressable Recommended for Screening Payment US Market Over 90% Gross Margin per Test 9
Slide 10: EsoGuard Revenue & Test Volume
EsoGuard Revenue & Test Volume $1,400,000 3,500 Revenue Tests $1,200,000 3,000 $1,000,000 2,500 $800,000 2,000 $600,000 1,500 $400,000 1,000 $200,000 500 $0 0 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 10
Slide 11: Business Update
Dlucid wes By Business Update
Slide 12: EsoGuard Clinical Evidence Base
EsoGuard Clinical Evidence Base Clinical Validity Pivotal Study BETRNet Study Cleveland VA Study ESOGUARD BE-1 Study Publication Design Prospective, multicenter case-control Prospective, multicenter case-control Prospective, single-center, single-arm Prospective, multicenter, single-arm Date Publish
Slide 13: ESOGUARD BE-1 Validation Study Accepted for Peer-Reviewed Publication
Lucid Diagnostics’ ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication BROBHES Publication, which once again demonstrates strong EsoGuard performance in a screening population, completes Lucid's clinical evi
Slide 14: Commercial Focus on Driving Revenue
Commercial Focus on Driving Revenue 1. Fully-Contracted #CYFT Precancer Testing Events 2. Concierge Medicine 3. Employer Markets 14
Slide 15: Q3 2024 Financial Update
Q3 2024 Financial Update Dennis McGrath, CFO
Slide 16: Balance Sheet
Balance Sheet ($ in thousands) 2Q24 3Q24 Change Assets Cash $24,920 $14,489 $(10,431) Fixed Assets 1,050 940 (110) All other Assets 8,143 7,169 (974) Liabilities Accounts Payable 903 1,135 232 Other Current Liabilities 15,077 13,114 (1,963) Long-Term Liabilities 2,154 2,011 (143) Shares Outstanding
Slide 17: P&L
P&L ($ in thousands) 3Q23 3Q24 Change 3Q23 - YTD 3Q24 - YTD Change Revenue $783 $1,172 $389 $1,388 $3,149 $1,761 Operating Expenses $11,911 $12,866 $955 $38,417 $36,826 $(1,591) Net Loss $(14,208) $(12,371) $1,837 $(41,836) $(33,988) $7,848 EBITDA $(13,550) $(12,236) $1,314 $(39,891) $(33,280) $6,61
Slide 18: Non-GAAP Operating Expense
Non-GAAP Operating Expense To supplement our audited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company’s financial results. Non-GAAP financial measures are presented with the int
Slide 19: Q&A
Q&A
Slide 20: Closing Remarks
Dlucid wes By Closing Remarks